Medprin Regenerative Medical Technologies Co., Ltd.
SZSE:301033 Stock Report
Market Cap: CN¥3.1b
Medprin Regenerative Medical Technologies Valuation
Is 301033 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 301033 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 301033 (CN¥46.51) is trading above our estimate of fair value (CN¥8.37)
Significantly Below Fair Value: 301033 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 301033?
Key metric: As 301033 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for 301033. This is calculated by dividing 301033's market cap by their current
earnings.
What is 301033's PE Ratio?
PE Ratio
44.8x
Earnings
CN¥68.26m
Market Cap
CN¥3.06b
301033 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: 301033 is expensive based on its Price-To-Earnings Ratio (44.8x) compared to the CN Medical Equipment industry average (34.9x).
Price to Earnings Ratio vs Fair Ratio
What is 301033's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
301033 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
44.8x
Fair PE Ratio
29.8x
Price-To-Earnings vs Fair Ratio: 301033 is expensive based on its Price-To-Earnings Ratio (44.8x) compared to the estimated Fair Price-To-Earnings Ratio (29.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.